U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363369) titled 'Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors' on Jan. 12.
Brief Summary: Cancer-associated fibroblasts (CAFs), as core regulators within the tumor microenvironment, significantly impede the intratumoral penetration of therapeutic agents and suppress the effective infiltration and activation of immune cells by constructing elaborate physical and functional barriers. Fibroblast activation protein (FAP) is a highly specific therapeutic target for CAFs, owing to its nearly tumor-restricted expression profile. Therefore, developing therapeutic strategies that specifically target FAP to e...